Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 1/2017

01-01-2017 | 2016 SSAT Plenary Presentation

A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database

Authors: Andrea Ruzzenente, Fabio Bagante, Francesca Bertuzzo, Luca Aldrighetti, Giorgio Ercolani, Felice Giuliante, Alessandro Ferrero, Guido Torzilli, Gian Luca Grazi, Francesca Ratti, Alessandro Cucchetti, Agostino M. De Rose, Nadia Russolillo, Matteo Cimino, Pasquale Perri, Ivana Cataldo, Aldo Scarpa, Alfredo Guglielmi, Calogero Iacono

Published in: Journal of Gastrointestinal Surgery | Issue 1/2017

Login to get access

Abstract

Even though surgery remains the only potentially curative option for patients with neuroendocrine liver metastases, the factors determining a patient’s prognosis following hepatectomy are poorly understood. Using a multicentric database including patients who underwent hepatectomy for NELMs at seven tertiary referral hepato-biliary-pancreatic centers between January 1990 and December 2014, we sought to identify the predictors of survival and develop a clinical tool to predict patient’s prognosis after liver resection for NELMs. The median age of the 238 patients included in the study was 61.9 years (interquartile range 51.5–70.1) and 55.9 % (n = 133) of patients were men. The number of NELMs (hazard ratio = 1.05), tumor size (HR = 1.01), and Ki-67 index (HR = 1.07) were the predictors of overall survival. These variables were used to develop a nomogram able to predict survival. According to the predicted 5-year OS, patients were divided into three different risk classes: 19.3, 55.5, and 25.2 % of patients were in low (>80 % predicted 5-year OS), medium (40–80 % predicted 5-year OS), and high (<40 % predicted 5-year OS) risk classes. The 10-year OS was 97.0, 55.9, and 20.0 % in the low, medium, and high-risk classes, respectively (p < 0.001). We developed a novel nomogram that accurately (c-index >70 %) staged and predicted the prognosis of patients undergoing liver resection for NELMs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Klimstra DS, Modlin IR, Coppola D et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39: 707–712.CrossRefPubMed Klimstra DS, Modlin IR, Coppola D et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39: 707–712.CrossRefPubMed
2.
go back to reference Yao JC, Hassan M, Phan A et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–3072.CrossRefPubMed Yao JC, Hassan M, Phan A et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26: 3063–3072.CrossRefPubMed
3.
go back to reference Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794–1803.CrossRefPubMed Garcia-Carbonero R, Capdevila J, Crespo-Herrero G et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21: 1794–1803.CrossRefPubMed
4.
go back to reference Lawrence B, Gustafsson BI, Chan A et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 1–18, vii.CrossRefPubMed Lawrence B, Gustafsson BI, Chan A et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40: 1–18, vii.CrossRefPubMed
5.
go back to reference Saxena A, Chua TC, Perera M et al. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol 2012; 21: e131-141.CrossRefPubMed Saxena A, Chua TC, Perera M et al. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol 2012; 21: e131-141.CrossRefPubMed
6.
go back to reference Frilling A, Modlin IM, Kidd M et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15: e8-21.CrossRefPubMed Frilling A, Modlin IM, Kidd M et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 2014; 15: e8-21.CrossRefPubMed
7.
go back to reference McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81: 1007–1009.CrossRefPubMed McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 1994; 81: 1007–1009.CrossRefPubMed
8.
go back to reference Rindi G, D’Adda T, Froio E et al. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007; 18: 145–149.CrossRefPubMed Rindi G, D’Adda T, Froio E et al. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007; 18: 145–149.CrossRefPubMed
9.
go back to reference Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015; 121: 1172–1186.CrossRefPubMed Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer 2015; 121: 1172–1186.CrossRefPubMed
10.
go back to reference Farley HA, Pommier RF. Treatment of Neuroendocrine Liver Metastases. Surg Oncol Clin N Am 2016; 25: 217–225.CrossRefPubMed Farley HA, Pommier RF. Treatment of Neuroendocrine Liver Metastases. Surg Oncol Clin N Am 2016; 25: 217–225.CrossRefPubMed
11.
go back to reference Ramage JK, Ahmed A, Ardill J et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61: 6–32.CrossRefPubMed Ramage JK, Ahmed A, Ardill J et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61: 6–32.CrossRefPubMed
12.
go back to reference Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009; CD007060. Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009; CD007060.
13.
go back to reference Bosman FT, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer 2010. Bosman FT, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer 2010.
14.
go back to reference Durante C, Boukheris H, Dromain C et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 2009; 16: 585–597.CrossRefPubMed Durante C, Boukheris H, Dromain C et al. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma. Endocr Relat Cancer 2009; 16: 585–597.CrossRefPubMed
15.
go back to reference Belgihiti J CP,, Gadzijev, et al. . The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000;2:333–9. Belgihiti J CP,, Gadzijev, et al. . The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000;2:333–9.
16.
go back to reference Frilling A, Li J, Malamutmann E et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009; 96: 175–184.CrossRefPubMed Frilling A, Li J, Malamutmann E et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009; 96: 175–184.CrossRefPubMed
17.
go back to reference Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 2008; 26: 1364–1370.CrossRefPubMed Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol 2008; 26: 1364–1370.CrossRefPubMed
18.
go back to reference Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361–387.CrossRefPubMed Harrell FE, Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361–387.CrossRefPubMed
19.
go back to reference Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.CrossRefPubMed Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29–36.CrossRefPubMed
20.
go back to reference Harrell FE. Regression modeling strategies : with applications to linear models, logistic regression, and survival analysis. New York: Springer 2001.CrossRef Harrell FE. Regression modeling strategies : with applications to linear models, logistic regression, and survival analysis. New York: Springer 2001.CrossRef
21.
go back to reference R Core Development Team. R: A Language and Environment for Statistical Computing. In. Vienna, Austria: R Foundation for Statistical Computing 2015. R Core Development Team. R: A Language and Environment for Statistical Computing. In. Vienna, Austria: R Foundation for Statistical Computing 2015.
22.
go back to reference Therneau TM, Grambsch PM. Modeling survival data : extending the Cox model. New York: Springer 2000.CrossRef Therneau TM, Grambsch PM. Modeling survival data : extending the Cox model. New York: Springer 2000.CrossRef
23.
go back to reference Frank E Harrell Jr with contributions from Charles Dupont and many others. Hmisc: Harrell Miscellaneous. In. 2016. Frank E Harrell Jr with contributions from Charles Dupont and many others. Hmisc: Harrell Miscellaneous. In. 2016.
24.
go back to reference Lesurtel M, Nagorney DM, Mazzaferro V et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford) 2015; 17: 17–22.CrossRef Lesurtel M, Nagorney DM, Mazzaferro V et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford) 2015; 17: 17–22.CrossRef
25.
go back to reference Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432–445.CrossRefPubMed Chamberlain RS, Canes D, Brown KT et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190: 432–445.CrossRefPubMed
26.
go back to reference Chen H, Hardacre JM, Uzar A et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 88–92; discussion 92–83.CrossRefPubMed Chen H, Hardacre JM, Uzar A et al. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998; 187: 88–92; discussion 92–83.CrossRefPubMed
27.
go back to reference Karabulut K, Akyildiz HY, Lance C et al. Multimodality treatment of neuroendocrine liver metastases. Surgery 2011; 150: 316–325.CrossRefPubMed Karabulut K, Akyildiz HY, Lance C et al. Multimodality treatment of neuroendocrine liver metastases. Surgery 2011; 150: 316–325.CrossRefPubMed
28.
go back to reference Landry CS, Scoggins CR, McMasters KM, Martin RC, 2nd. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 2008; 97: 253–258.CrossRefPubMed Landry CS, Scoggins CR, McMasters KM, Martin RC, 2nd. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 2008; 97: 253–258.CrossRefPubMed
29.
go back to reference Mayo SC, de Jong MC, Bloomston M et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011; 18: 3657–3665.CrossRefPubMed Mayo SC, de Jong MC, Bloomston M et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 2011; 18: 3657–3665.CrossRefPubMed
30.
go back to reference Musunuru S, Chen H, Rajpal S et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006; 141: 1000–1004; discussion 1005.CrossRefPubMed Musunuru S, Chen H, Rajpal S et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 2006; 141: 1000–1004; discussion 1005.CrossRefPubMed
31.
go back to reference Osborne DA, Zervos EE, Strosberg J et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13: 572–581.CrossRefPubMed Osborne DA, Zervos EE, Strosberg J et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13: 572–581.CrossRefPubMed
32.
go back to reference Saxena A, Chua TC, Zhao J, Morris DL. Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. J Surg Oncol 2012; 105: 342–350.CrossRefPubMed Saxena A, Chua TC, Zhao J, Morris DL. Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. J Surg Oncol 2012; 105: 342–350.CrossRefPubMed
33.
go back to reference Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776–783; discussion 783–775.CrossRefPubMedPubMedCentral Touzios JG, Kiely JM, Pitt SC et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005; 241: 776–783; discussion 783–775.CrossRefPubMedPubMedCentral
34.
go back to reference Yao KA, Talamonti MS, Nemcek A et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130: 677–682; discussion 682–675.CrossRefPubMed Yao KA, Talamonti MS, Nemcek A et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001; 130: 677–682; discussion 682–675.CrossRefPubMed
35.
go back to reference Mayo SC, de Jong MC, Pulitano C et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17: 3129–3136.CrossRefPubMed Mayo SC, de Jong MC, Pulitano C et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17: 3129–3136.CrossRefPubMed
36.
go back to reference Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumours. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell 2010. Sobin LH, Gospodarowicz MK, Wittekind C, International Union against Cancer. TNM classification of malignant tumours. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell 2010.
37.
go back to reference Pelosi G, Bresaola E, Bogina G et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27: 1124–1134.CrossRefPubMed Pelosi G, Bresaola E, Bogina G et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27: 1124–1134.CrossRefPubMed
38.
go back to reference Cho CS, Labow DM, Tang L et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 2008; 113: 126–134.CrossRefPubMed Cho CS, Labow DM, Tang L et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 2008; 113: 126–134.CrossRefPubMed
39.
go back to reference Nave H, Mossinger E, Feist H et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001; 129: 170–175.CrossRefPubMed Nave H, Mossinger E, Feist H et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001; 129: 170–175.CrossRefPubMed
40.
go back to reference Saxena A, Chua TC, Sarkar A et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011; 149: 209–220.CrossRefPubMed Saxena A, Chua TC, Sarkar A et al. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011; 149: 209–220.CrossRefPubMed
41.
go back to reference Hibi T, Sano T, Sakamoto Y et al. Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan. Jpn J Clin Oncol 2007; 37: 102–107.CrossRefPubMed Hibi T, Sano T, Sakamoto Y et al. Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan. Jpn J Clin Oncol 2007; 37: 102–107.CrossRefPubMed
42.
go back to reference Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall 1993.CrossRef Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall 1993.CrossRef
Metadata
Title
A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database
Authors
Andrea Ruzzenente
Fabio Bagante
Francesca Bertuzzo
Luca Aldrighetti
Giorgio Ercolani
Felice Giuliante
Alessandro Ferrero
Guido Torzilli
Gian Luca Grazi
Francesca Ratti
Alessandro Cucchetti
Agostino M. De Rose
Nadia Russolillo
Matteo Cimino
Pasquale Perri
Ivana Cataldo
Aldo Scarpa
Alfredo Guglielmi
Calogero Iacono
Publication date
01-01-2017
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 1/2017
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-016-3228-6

Other articles of this Issue 1/2017

Journal of Gastrointestinal Surgery 1/2017 Go to the issue